Stocks and Investing
Stocks and Investing
Fri, November 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, November 10, 2022
Anthony Petrone Maintained (ADMA) at Strong Buy with Increased Target to $6 on, Nov 10th, 2022
Anthony Petrone of Mizuho, Maintained "ADMA Biologics, Inc." (ADMA) at Strong Buy with Increased Target from $5 to $6 on, Nov 10th, 2022.
Anthony has made no other calls on ADMA in the last 4 months.
There is 1 other peer that has a rating on ADMA. Out of the 1 peers that are also analyzing ADMA, 0 agree with Anthony's Rating of Hold.
This is the rating of the analyst that currently disagrees with Anthony
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $4 on, Monday, July 25th, 2022
Contributing Sources